This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoosein, N. M. Articles by Brattain, M. G. Search for Related Content PubMed PubMed Citation Articles by Hoosein, N. M. Articles by Brattain, M. G.

Characterization of the Inhibitory Effects of Transforming Growth Factor-ß on a Human Colon Carcinoma Cell Line¹

Bristol-Baylor Laboratory, Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030

The effects of transforming growth factor-ß (TGFß) on a human colon carcinoma cell line (MOSER) were investigated. TGFß, at low concentrations (between 0.1 and 1.0 ng/ml), inhibited the proliferation of MOSER cells both in monolayer culture and soft agarose, in a dosedependent manner. MOSER cells adapted to growth in chemically defined serum-free medium were more sensitive to the inhibitory effects of TGFß than cells maintained in serum-supplemented medium. Morphological changes in MOSER cells, observed with TGFß, were similar to those seen with the chemical differentiation agent N,N-dimethylformamide. Also in similarity to the effects of N,N-dimethylformamide, TGFß induced a time- and concentration-dependent increase in soluble extracellular fibronectin. Binding studies with [¹²⁵I]TGFß revealed a relatively low number of binding sites on MOSER cells (13%) compared with mouse embryo fibroblastic (AKR-2B) cells. Thus far, other colon carcinoma cell lines, some displaying TGFß receptors, have been reported to be unresponsive to TGFß. This study is therefore the first to demonstrate a TGFß-responsive colon carcinoma cell line.

¹ Supported by NIH Grant CA34432 and American Cancer Society Grant BC-492.

² To whom requests for reprints should be addressed, at Bristol-Baylor Laboratory, Department of Pharmacology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030.

Received 8/25/86. Revised 2/17/87. Accepted 3/10/87.

This article has been cited by other articles:

				J. L. Dai, R. K. Bansal, and S. E. Kern G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: Phenotypes reversed by a tumorigenic mutation PNAS, February 16, 1999; 96(4): 1427 - 1432. [Abstract] [Full Text] [PDF]

				S. Zhou, P. Buckhaults, L. Zawel, F. Bunz, G. Riggins, J. Le Dai, S. E. Kern, K. W. Kinzler, and B. Vogelstein Targeted deletion of Smad4 shows it is required for transforming growth factor beta  and activin signaling in colorectal cancer cells PNAS, March 3, 1998; 95(5): 2412 - 2416. [Abstract] [Full Text] [PDF]

				M. T. Hartsough and K. M. Mulder Transforming Growth Factor beta Activation of p44[IMAGE] in Proliferating Cultures of Epithelial Cells J. Biol. Chem., March 31, 1995; 270(13): 7117 - 7124. [Abstract] [Full Text] [PDF]

				S. Kirkland and K Henderson Endocrine and mucous differentiation by a cloned human rectal adenocarcinoma cell line (HRA-19) in vitro: inhibition by TGF-beta 1 J. Cell Sci., January 4, 1994; 107(4): 1041 - 1046. [Abstract] [PDF]